ArticleBriefings in bioinformatics2025
MVSGDR: multi-view stacked graph convolutional network for drug repositioning.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Drug repositioning (DR) presents a cost-effective strategy for drug development by identifying novel therapeutic applications for existing drugs. Current computational approaches remain constrained by their inability to synergize localized substructure patterns with global network semantics, leading to overreliance on data augmentation to mitigate latent drug-disease association (DDA) information gaps. To address these limitations, we present multi-view stacked graph convolutional network (MVSGDR), a novel DR framework featuring three technical innovations: (i) multi-view stacked module that enables depth-wise feature enhancement through hierarchical aggregation of multi-hop neighborhood interactions across distinct graph convolutional layers; (ii) bi-level subgraph transformer module that decomposes DDAs into METIS (a graph partitioning tool) informative subgraphs for breadth-wise analysis of external and internal subgraph drug-disease relationships; and (iii) negative sampling balancing strategy that mitigates sample imbalance through negative sample synthesis. Extensive 10-fold cross-validation experiments across four benchmark datasets confirm MVSGDR's superior performance, demonstrating its statistically significant improvements over existing methods. Moreover, case studies further validate MVSGDR's potential utility through identification of previously unreported DDAs with supporting literature evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.